PCSK9与降脂药研究进展  

Research progress in PCSK9 and lipid lowering drugs

作　　者：张伟[1] 周冰洋[2] 郭远林[2] 李建军[2] 

机构地区：[1]北京医院,北京100730 [2]国家心血管病中心&阜外医院,北京100037

出　　处：《中国新药杂志》2017年第9期1016-1023,共8页Chinese Journal of New Drugs

基　　金：国家自然科学基金资助项目(81070171;81241121);高等学校博士学科点专项科研基金资助项目(20111106110013);首都临床特色应用研究资助项目(Z121107001012015);阜外医院院所青年基金资助项目(2010-F02)

摘　　要：前蛋白转化酶枯草溶菌素/kexin9型(PCSK9)是一种新型循环蛋白,在胆固醇代谢调节过程中起着重要作用。在过去十几年中,实验研究和临床研究已经证实,PCSK9过度表达或低表达不仅会影响循环PCSK9和低密度脂蛋白胆固醇(LDL-C)水平,还会对心血管风险和动脉粥样硬化产生重大影响。自从2003年首次发现PCSK9相关基因以来,可以影响循环PCSK9浓度的因素引起了医学界各方的极大关注,尤其是药理学界。本综述重点关注降脂药对循环PCSK9浓度的影响及其临床意义,以期为优化当前的胆固醇控制策略提供思路。Proprotein convertase subtilisin/kexin type 9 （PCSK9） is a novel circulating protein, which plays an important role in the regulation of cholesterol metabolism. Over the past decade, experimental and clinical studies have established that over- or poor expression of PCSK9 has a key impact not only on circulating PCSK9 and low density lipoprotein cholesterol （LDL-C） levels but also on cardiovascular risk and atherosclerotic process. Since the first discovery of PCSK9-related gene in 2003, factors that can influence circulating PCSK9 concentration are of great interest in a variety of medical fields, especially in pharmacology. In this review we focus on the impact of lipid-lowering drugs on circulating PCSK9 concentration and its clinical implications in order to provide new considerations for optimizing current strategies with regard to cholesterol control.

关 键 词：前蛋白转化酶枯草溶菌素/kexin9型 低密度脂蛋白胆固醇 血脂 降脂药 药理作用 

分 类 号：R972.6[医药卫生—药品]